The Clinical Effect Of PEG-rhG-CSF And RhG-CSF On The Prevention Of Chemotherapy Neutropenia In Patients With Osteosarcoma

Objective:To compare the clinical efficacy of Pegylated recombinant human granulocyte stimulating factor(PEG-rh G-CSF)and Recombinant Human Granulocyte Stimulating Factor(rh G-CSF)in the prevention of neutropenia after chemotherapy in patients with osteosarcoma.Methods:This study is a retrospective analysis.The 90newly-treated osteosarcoma patients admitted to this hospital from January 2015 to May2020 were selected to receive osteosarcoma neoadjuvant chemotherapy.The experiment was divided into three groups:group A was treated with rh G-CSF,5μg/kg,qd,subcutaneous injection group B was treated with rh G-CSF,5μg/kg,q12h,subcutaneous injection.In group C,the dose of PEG-rh G-CSF,injection body weight≥45 kg,6mg once,ang body weight<45 kg,3mg once,subcutaneous injection at a time.(One subcutaneous injection 48 hours after the end of the course of chemotherapy.)Until the absolute value of peripheral blood neutrophils(ANC)reached the trough,the drug was stopped twice in a row when the peripheral blood ANC was≥5.0×10~9/L or once the peripheral blood ANC was≥10.0×10~9/L.Statistics on the time to drug compliance of the three groups of patients,the incidence of grade III bone marrow suppression,the incidence of grade IV bone marrow suppression,the duration of gradeⅣbone marrow suppression,the use rate of antibacterial drugs,the incidence of febrile neutropenia,and the cost of medication for the three groups Learn analysis.Results:There was a significant difference in the number of days of medication compliance between the three groups A,B,and C.The average medication time of group C was(4.88±2.251)days,which was lower than the other two groups.The difference was statistically significant,P=0.000.The three groups compared the cost of G-CSF treatment.The average cost of group B was 4562.07 yuan,which was higher than that of the other two groups.The difference was statistically significant,P=0.000.The ANC value measured before the next cycle of chemotherapy in group C was higher than that in group B,with statistical difference,P=0.005.There was no statistical difference in the incidence of FN,antibiotic use rate,the incidence of grade III bone marrow suppression,the incidence of grade IV bone marrow suppression,and the duration of grade IV bone marrow suppression in the three groups,P>0.05.Conclusion:Polyethylene glycol recombinant human granulocyte stimulating factor after neoadjuvant chemotherapy in Uygur Osteosarcoma,the recovery time of neutrophils is shorter and less expensive than that of recombinant human granulocyte colony stimulating factor.However,PEG-rh G-CSF only requires one administration,which is more convenient and has good patient compliance,which is worthy of clinical promotion.